GlassScriptPhysician profile
Susan Bal
NPI 1831451129
$47,349.05
in general payments reported to CMS, 2019-2025
16 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,325 · 2023: $11K · 2024: $14K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Travel and Lodging: $9,184 · Food and Beverage: $1,308 · Education: $37.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,494.50 |
| Travel and Lodging | $9,183.91 |
| Food and Beverage | $1,308.43 |
| Education | $37.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $26,874.21 | 2023-2025 | Abecma |
| Celgene Corporation | $8,260.17 | 2024-2025 | |
| Abbvie INC. | $2,475.00 | 2023-2024 | Venclexta |
| Kite Pharma, INC. | $2,445.00 | 2025 | |
| Genentech, INC. | $1,875.00 | 2023 | Venclexta |
| Janssen Biotech, INC. | $1,755.00 | 2024 | Tecvayli |
| Astrazeneca Pharmaceuticals LP | $1,370.00 | 2023 | |
| Adaptive Biotechnologies Corporation | $1,200.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $817.50 | 2023 | |
| Pfizer INC. | $126.67 | 2023-2024 | |
| Amgen INC. | $125.00 | 2020 | |
| Legend Biotech USA INC. | $25.50 | 2024 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Bal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.